US Drug Recall Register

FDA Drug Recalls

14,801 recalls, newest first

Class I · High risk Terminated

8.4% Sodium Bicarbonate Injection

Reason Presence of Particulate Matter; glass particulates

Pfizer Inc. NDC 0409-6625-02 D-1073-2019
Class III · Low risk Terminated

Clindamycin Injection

Reason Failed Impurities/Degradation Specifications: High out-of-specification (OOS) results were demonstrated for several specified impurities at the 24-month time point

Pfizer Inc. NDC 47781-621-94 D-1072-2019
Class III · Low risk Terminated

Clindamycin Injection

Reason Failed Impurities/Degradation Specifications: High out-of-specification (OOS) results were demonstrated for several specified impurities at the 24-month time point

Pfizer Inc. NDC 47781-620-94 D-1071-2019
Class III · Low risk Terminated

Clindamycin Injection

Reason Failed Impurities/Degradation Specifications: High out-of-specification (OOS) results were demonstrated for several specified impurities at the 24-month time point

Pfizer Inc. NDC 47781-619-94 D-1070-2019
Class III · Low risk Terminated

Cleocin Phosphate

Reason Failed Impurities/Degradation Specifications: High out-of-specification (OOS) results were demonstrated for several specified impurities at the 24-month time point

Pfizer Inc. NDC 0009-3447-01 D-1069-2019
Class III · Low risk Terminated

Cleocin Phosphate

Reason Failed Impurities/Degradation Specifications: High out-of-specification (OOS) results were demonstrated for several specified impurities at the 24-month time point

Pfizer Inc. NDC 0009-3124-01 D-1068-2019
Class III · Low risk Terminated

Cleocin Phosphate

Reason Failed Impurities/Degradation Specifications: High out-of-specification (OOS) results were demonstrated for several specified impurities at the 24-month time point

Pfizer Inc. NDC 0009-6582-02 D-1067-2019
Class I · High risk Terminated

Blue Fusion Capsules

Reason Marketed Without An Approved NDA/ANDA: FDA analysis found this product to contain undeclared ingredients: Sildenafil, Tadalafil, desmethyl carbodenafil, dithiodesmethyl carbodenafil, scutellarin, and daidzein.

Ata International Inc D-1085-2019
Class II · Moderate risk Terminated

Losartan 50mg Tablet

Reason CGMP Deviations; Detection of trace amounts of an unexpected impurity found in an active pharmaceutical ingredient (API) - N-Methylnitrosobutyric acid (NMBA).

RemedyRepack Inc. D-1081-2019
Class II · Moderate risk Terminated

Phenylephrine HCl

Reason Lack of Assurance of Sterility

Advanced Pharma Inc. D-1034-2019
Class II · Moderate risk Terminated

Morphine Sulfate 30 mg/30 mL

Reason Lack of Assurance of Sterility

Advanced Pharma Inc. D-1033-2019
Class II · Moderate risk Terminated

Phenylephrine HCl

Reason Lack of Assurance of Sterility

Advanced Pharma Inc. D-1032-2019
Class II · Moderate risk Terminated

Heparin 5

Reason Lack of Assurance of Sterility

Advanced Pharma Inc. D-1031-2019
Class II · Moderate risk Terminated

Phenylephrine HCl

Reason Lack of Assurance of Sterility

Advanced Pharma Inc. D-1028-2019
Class II · Moderate risk Terminated

Glycopyrrolate 0.6 mg/3 mL

Reason Lack of Assurance of Sterility

Advanced Pharma Inc. D-1025-2019
Class II · Moderate risk Terminated

Phenylephrine HCl

Reason Lack of Assurance of Sterility

Advanced Pharma Inc. D-1023-2019
Class II · Moderate risk Terminated

Phenylephrine HCl

Reason Lack of Assurance of Sterility

Advanced Pharma Inc. D-1022-2019
Class II · Moderate risk Terminated

Phenylephrine HCl

Reason Lack of Assurance of Sterility

Advanced Pharma Inc. D-1020-2019